NJ State Employees Deferred Compensation Plan’s AbbVie ABBV Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,184	Closed	-$3.05M	–	3
2025 Q3	$3.05M	Sell	13,184 -1,780	-12%	-$362K	0.34%	65
2025 Q2	$2.78M	Hold	14,964	–	–	0.33%	70
2025 Q1	$3.14M	Hold	14,964	–	–	0.4%	55
2024 Q4	$2.66M	Sell	14,964 -4,000	-21%	-$735K	0.32%	69
2024 Q3	$3.75M	Hold	18,964	–	–	0.44%	46
2024 Q2	$3.25M	Hold	18,964	–	–	0.4%	50
2024 Q1	$3.45M	Hold	18,964	–	–	0.44%	53
2023 Q4	$2.94M	Sell	18,964 -4,000	-17%	-$583K	0.4%	55
2023 Q3	$3.42M	Hold	22,964	–	–	0.52%	40
2023 Q2	$3.09M	Hold	22,964	–	–	0.45%	50
2023 Q1	$3.66M	Hold	22,964	–	–	0.57%	38
2022 Q4	$3.71M	Hold	22,964	–	–	0.6%	34
2022 Q3	$3.08M	Hold	22,964	–	–	0.53%	46
2022 Q2	$3.52M	Hold	22,964	–	–	0.57%	39
2022 Q1	$3.72M	Hold	22,964	–	–	0.5%	44
2021 Q4	$3.11M	Hold	22,964	–	–	0.39%	65
2021 Q3	$2.48M	Hold	22,964	–	–	0.34%	79
2021 Q2	$2.59M	Hold	22,964	–	–	0.34%	73
2021 Q1	$2.48M	Hold	22,964	–	–	0.35%	74
2020 Q4	$2.46M	Hold	22,964	–	–	0.38%	72
2020 Q3	$2.01M	Hold	22,964	–	–	0.36%	71
2020 Q2	$2.25M	Buy	22,964 +4,330	+23%	+$381K	0.42%	62
2020 Q1	$1.42M	Hold	18,634	–	–	0.32%	76
2019 Q4	$1.65M	Hold	18,634	–	–	0.28%	86
2019 Q3	$1.41M	Hold	18,634	–	–	0.26%	93
2019 Q2	$1.35M	Hold	18,634	–	–	0.24%	95
2019 Q1	$1.5M	Sell	18,634 -5,000	-21%	-$409K	0.27%	88
2018 Q4	$2.18M	Hold	23,634	–	–	0.45%	51
2018 Q3	$2.23M	Buy	+23,634	New	+$2.24M	0.38%	60
2018 Q2	–	Sell	-40,000	Closed	-$3.79M	–	501
2018 Q1	$3.79M	Hold	40,000	–	–	0.67%	27
2017 Q4	$3.87M	Hold	40,000	–	–	0.67%	26
2017 Q3	$3.55M	Hold	40,000	–	–	0.64%	30
2017 Q2	$2.9M	Hold	40,000	–	–	0.55%	38
2017 Q1	$2.61M	Hold	40,000	–	–	0.5%	45
2016 Q4	$2.5M	Hold	40,000	–	–	0.5%	49
2016 Q3	$2.52M	Hold	40,000	–	–	0.52%	43
2016 Q2	$2.48M	Hold	40,000	–	–	0.53%	44
2016 Q1	$2.4M	Hold	40,000	–	–	0.51%	44
2015 Q4	$2.37M	Hold	40,000	–	–	0.49%	49
2015 Q3	$2.18M	Buy	40,000 +30,000	+300%	+$1.95M	0.47%	50
2015 Q2	$672K	Hold	10,000	–	–	0.13%	252
2015 Q1	$585K	Hold	10,000	–	–	0.11%	273
2014 Q4	$654K	Hold	10,000	–	–	0.13%	255
2014 Q3	$578K	Hold	10,000	–	–	0.12%	277
2014 Q2	$564K	Hold	10,000	–	–	0.11%	291
2014 Q1	$514K	Hold	10,000	–	–	0.11%	294
2013 Q4	$528K	Hold	10,000	–	–	0.11%	297
2013 Q3	$447K	Hold	10,000	–	–	0.1%	309
2013 Q2	$413K	Buy	+10,000	New	+$437K	0.09%	314

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ABBV Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 13,184 shares — an estimated $3.05M sold.

NJ State Employees Deferred Compensation Plan first reported a position in ABBV in Q2 2013 and held it in 49 quarters. The position peaked at $3.87M in Q4 2017. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 13,184 AbbVie shares in Q4 2025, an estimated $3.05M.
NJ State Employees Deferred Compensation Plan first reported a position in AbbVie in Q2 2013 and held it in 49 quarters.
NJ State Employees Deferred Compensation Plan's AbbVie position peaked at $3.87M in Q4 2017.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.